160 related articles for article (PubMed ID: 26240005)
1. Proton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis.
van Aerts RM; van Deursen CT; Koek GH
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):147-52. PubMed ID: 26240005
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial.
Vanclooster A; van Deursen C; Jaspers R; Cassiman D; Koek G
Gastroenterology; 2017 Sep; 153(3):678-680.e2. PubMed ID: 28624580
[TBL] [Abstract][Full Text] [Related]
3. The modified iron avidity index: a promising phenotypic predictor in HFE-related haemochromatosis.
Verhaegh PL; Moris W; Koek GH; van Deursen CT
Liver Int; 2016 Oct; 36(10):1535-9. PubMed ID: 26992127
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.
Barton JC; Barton JC; Acton RT; So J; Chan S; Adams PC
Clin Gastroenterol Hepatol; 2012 Apr; 10(4):412-6. PubMed ID: 22265917
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors reduce phlebotomy burden in patients with HFE-related hemochromatosis: a systematic review and meta-analysis.
Dirweesh A; Anugwom CM; Li Y; Vaughn BP; Lake J
Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1327-1331. PubMed ID: 32769410
[TBL] [Abstract][Full Text] [Related]
6. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract][Full Text] [Related]
7. Absorption of nonheme iron during gastric acid suppression in patients with hereditary hemochromatosis and healthy controls.
Moris W; Verhaegh PLM; Verbeek J; Swinkels DW; Laarakkers CM; Masclee AAM; Koek GH; Deursen CTBMV
Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1105-G1110. PubMed ID: 33949198
[TBL] [Abstract][Full Text] [Related]
8. Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis.
Sangwaiya A; Manglam V; Busbridge M; Thursz M; Arnold J
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):721-4. PubMed ID: 21654321
[TBL] [Abstract][Full Text] [Related]
9. [Management of hemochromatosis linked to HFE gene].
Brissot P; De Bels F
Presse Med; 2007 Sep; 36(9 Pt 2):1295-300. PubMed ID: 17553656
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
Poullin P; Lefèvre PA
Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
12. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients.
Santos PC; Cançado RD; Pereira AC; Schettert IT; Soares RA; Pagliusi RA; Hirata RD; Hirata MH; Teixeira AC; Figueiredo MS; Chiattone CS; Krieger JE; Guerra-Shinohara EM
Blood Cells Mol Dis; 2011 Apr; 46(4):302-7. PubMed ID: 21411349
[TBL] [Abstract][Full Text] [Related]
13. Hemochromatosis and iron-overload screening in a racially diverse population.
Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P;
N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186
[TBL] [Abstract][Full Text] [Related]
14. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels.
van Dijk BA; Laarakkers CM; Klaver SM; Jacobs EM; van Tits LJ; Janssen MC; Swinkels DW
Br J Haematol; 2008 Sep; 142(6):979-85. PubMed ID: 18557745
[TBL] [Abstract][Full Text] [Related]
15. Increased DMT1 but not IREG1 or HFE mRNA following iron depletion therapy in hereditary haemochromatosis.
Kelleher T; Ryan E; Barrett S; Sweeney M; Byrnes V; O'Keane C; Crowe J
Gut; 2004 Aug; 53(8):1174-9. PubMed ID: 15247188
[TBL] [Abstract][Full Text] [Related]
16. [Molecular genetic diagnostics and screening of hereditary hemochromatosis].
Zlocha J; Kovács L; Pozgayová S; Kupcová V; Durínová S
Vnitr Lek; 2006 Jun; 52(6):602-8. PubMed ID: 16871764
[TBL] [Abstract][Full Text] [Related]
17. A population-based study of the clinical expression of the hemochromatosis gene.
Olynyk JK; Cullen DJ; Aquilia S; Rossi E; Summerville L; Powell LW
N Engl J Med; 1999 Sep; 341(10):718-24. PubMed ID: 10471457
[TBL] [Abstract][Full Text] [Related]
18. [Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations].
Fernández-Mosteirín N; Salvador-Osuna C; García-Erce JA; Orna E; Pérez-Lungmus G; Giralt M
Med Clin (Barc); 2006 Sep; 127(11):409-12. PubMed ID: 17020684
[TBL] [Abstract][Full Text] [Related]
19. Hereditary hemochromatosis: the clinical significance of the S65C mutation.
Asberg A; Thorstensen K; Hveem K; Bjerve KS
Genet Test; 2002; 6(1):59-62. PubMed ID: 12180078
[TBL] [Abstract][Full Text] [Related]
20. Iron-overload-related disease in HFE hereditary hemochromatosis.
Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
